Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Accounts Payables (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Accounts Payables for 15 consecutive years, with $33.3 million as the latest value for Q1 2026.

  • For Q1 2026, Accounts Payables rose 19.18% year-over-year to $33.3 million; the TTM value through Mar 2026 reached $33.3 million, up 19.18%, while the annual FY2025 figure was $40.4 million, 163.03% up from the prior year.
  • Accounts Payables hit $33.3 million in Q1 2026 for Corcept Therapeutics, down from $40.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $40.4 million in Q4 2025 and bottomed at $8.0 million in Q2 2023.
  • Average Accounts Payables over 5 years is $18.6 million, with a median of $16.7 million recorded in 2023.
  • Year-over-year, Accounts Payables decreased 11.61% in 2024 and then skyrocketed 163.03% in 2025.
  • Corcept Therapeutics' Accounts Payables stood at $12.0 million in 2022, then soared by 45.26% to $17.4 million in 2023, then decreased by 11.61% to $15.4 million in 2024, then skyrocketed by 163.03% to $40.4 million in 2025, then fell by 17.65% to $33.3 million in 2026.
  • According to Business Quant data, Accounts Payables over the past three periods came in at $33.3 million, $40.4 million, and $34.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.